Monoclonal antibodies, or mAbs, are important tools in medicine. These laboratory-made proteins are widely used in treatments ...

Viruses are masters at disguise. When they are pushed too far by our immune system, they send new virus variants into play ...

Researchers at Durham University have achieved a major advancement in understanding how proteins bind metals inside cells, a process crucial to life. The study, published in Nature Communications, ...

Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed strong safety and efficacy, with plans for a phase 2 trial in 2025.

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw some participants achieving an 88.94% reduction in viral load.

Researchers have found a new way to reduce the effects of pre-eclampsia using mRNA-lipid nanoparticle therapies.

Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced promising topline data from the completed Phase 1 clinical trial of its lead mRNA ...

Discover the top genomics startups revolutionizing genome sequencing technologies to enhance disease prevention and treatment ...

EZH1 is a key regulator of circadian rhythms, stabilizing gene transcription and modifying chromatin to maintain genetic ...

Researchers have developed ProtET, a cutting-edge AI model that uses multi-modal learning to enable precise, text-guided protein editing, paving the way for breakthroughs in biotechnology and medicine ...

Researchers at Durham University have achieved a major advancement in understanding how proteins bind metals inside cells, a process crucial to life.